Current status of medical insurance reimbursement for lung cancer drug Ripotinib (Augtyro)

Repotrectinib (Repotrectinib), with trade names including Augtyro and Augtyro, is a new generation of tyrosine kinase inhibitor (TKI) anti-cancer drug for ROS1-positive non-small cell lung cancer (NSCLC). In ROS1-positive NSCLC, partial combination of the ROS1 gene with another gene can lead to abnormal activation of the ROS1 gene, thereby promoting uncontrolled cell growth and forming tumors. Ripotinib effectively blocks this signaling pathway by inhibiting the ROS1 gene and its downstream tyrosine kinase receptor, thereby controlling the growth of cancer and possibly shrinking tumors.

In recent years, Ripotinib has been included in the scope of national medical insurance (medical insurance), which means that eligible patients can enjoy a certain reimbursement rate when purchasing this drug. The implementation of this policy aims to reduce the financial pressure on patients and enable more lung cancer patients to receive timely and effective treatment. At present, the current status of medical insurance reimbursement for Ripotinib varies from region to region, and the medical insurance bureaus in various regions have different reimbursement ratios and specific conditions. Generally speaking, patients need to provide relevant diagnosis certificates and prescriptions when applying for medical insurance reimbursement, and ensure that the drugs purchased comply with the scope of medication prescribed by medical insurance.

It should be noted that although repotinib has been included in medical insurance, some patients may not be eligible for reimbursement due to various reasons. In this regard, a generic version of Ripotinib has been launched on the Laotian market. The version produced by Lucius Pharmaceuticals has a specification of 40mg*60 pills and is priced at more than 3,000 yuan per box. Compared with the original drug, it has significantly reduced the financial burden of patients and made the drug more accessible to more patients.

For patients who choose to purchase Ripotinib, they must purchase it through formal channels to ensure the authenticity and safety of the drug. After receiving the medicine, patients should carefully identify the authenticity of the medicine and confirm the product name, specifications, manufacturer, expiration date and other information to avoid purchasing fake and shoddy products, which will affect the treatment effect. At the same time, patients should strictly follow the doctor's instructions when using the medicine, and if they have any adverse reactions, they should seek medical treatment in time.

In short, as an emerging targeted drug for lung cancer, repotinib has been recognized in my country’s medical insurance system, providing protection for many lung cancer patients. However, the specific situation of medical insurance reimbursement requires patients to consult the local medical insurance bureau according to the policies of their region in order to obtain accurate information.

References:

https://www.drugs.com/augtyro.html